title: Imatinib and pregnancy.
authors.forename: Ridvan
authors.initials: R
authors.lastname: Ali
authors.forename: Fahir
authors.initials: F
authors.lastname: Ozkalemkas
authors.forename: Tulay
authors.initials: T
authors.lastname: Ozcelik
authors.forename: Vildan
authors.initials: V
authors.lastname: Ozkocaman
authors.forename: Atilla
authors.initials: A
authors.lastname: Ozkan
mesh_terms: D000022:Abortion, Spontaneous / Q000139:chemically induced; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D000013:Congenital Abnormalities / Q000209:etiology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011264:Pregnancy Trimesters; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013723:Teratogens
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013723:Teratogens; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases